A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)
Condition(s):Chronic Lymphocytic LeukemiaLast Updated:February 27, 2020Completed
Hide Studies Not Open or Pending
Condition(s):Chronic Lymphocytic LeukemiaLast Updated:February 27, 2020Completed
Condition(s):Autoimmune Hemolytic Anemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Monoclonal B-Cell Lymphocytosis CLL-TypeLast Updated:December 1, 2023Recruiting
Condition(s):LeukemiaLast Updated:February 24, 2020Completed
Condition(s):Chronic Lymphocytic Leukemia; Mantle Cell LymphomaLast Updated:October 24, 2022Completed
Condition(s):LymphomaLast Updated:February 28, 2019Terminated
Condition(s):Leukemia, Lymphocytic, Chronic, B-CellLast Updated:April 29, 2016Unknown status
Condition(s):HealthyLast Updated:March 29, 2018Completed
Condition(s):Carcinoid Tumors; Pancreatic NETLast Updated:September 11, 2020Completed
Condition(s):Chronic Lymphocytic Leukemia; Waldenstrom Macroglobulinemia; Mantle Cell Lymphoma; Marginal Zone LymphomaLast Updated:February 5, 2020Withdrawn
Condition(s):Leukemia, Lymphocytic, Chronic, B-CellLast Updated:January 3, 2022Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.